LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease

  title={LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease},
  author={Stephen C. Pflugfelder and Michael Stern and Steven Zhang and Amir Shojaei},
  journal={Journal of Ocular Pharmacology and Therapeutics},
  pages={5 - 12}
Dry eye disease (DED) is a common ocular disorder associated with inflammation of the lacrimal gland and ocular surface. [] Key Result The results of our review suggest that LFA-1/ICAM-1 interaction may play important roles in the cell-mediated immune response and inflammation associated with DED, including facilitating the homing of dendritic cells to the lymph nodes, interaction of dendritic cells with T cells and subsequent T cell activation/differentiation, migration of activated CD4+ T cells from the…

Figures from this paper

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues

The results demonstrated that one of these analogues of Lifitegrast showed good LFA-1/ICAM-1 antagonist activity in in vitro assay; meanwhile, it also significantly reduced ocular surface epithelial cells damage, increased goblet cell density in dry eye mouse and highly improved the symptoms of dry eye mice.

A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye

A multivalent biopolymeric nanoparticle assembled from a diblock elastin-like polypeptide (ELP) using the S48I48 (SI) ELP scaffold fused with a mouse ICAM-1 targeting peptide to form IBP-SI is introduced, suggesting that a biopolymer nanoparticle with affinity for ICam-1 can disrupt ICAM and LFA interactions in vitro and may have further utility as an in vivo tool or potential therapeutic.

LFA-1/ ICAM-1 promotes NK cell cytotoxicity associated with the pathogenesis of ocular toxoplasmosis in murine model

The interaction between LFA-1 and ICAM-1 plays a role in the early regulation of the CD49a+ NK-cell proportion in an OT murine model, and may provide new insights for potential immunotherapy.

Analysis of Several Inflammatory Markers Expression in Obese Rats given Plectranthus amboinicus (Lour.) Spreng Ethanol Extract

VCAM-1 serves as a ligand for lymphocyte function-associated antigen 1 (LFA-1) and binds the leukocytes to endothelial cells, allowing the cells to migrate to the tissues.

Interleukin-20 is involved in dry eye disease and is a potential therapeutic target

The functions of IL-20 were demonstrated in DED and presented a potential therapeutic option for this condition and the anti-IL-20 antibody 7E was established to neutralize IL- 20 activity.

Pharmacological blockage of ICAM-1 improves angiotensin II-induced cardiac remodeling by inhibiting adhesion of LFA-1+ monocytes.

Novel evidence is provided that blocking ICAM-1 exerts a protective effect in Ang II-induced cardiac remodeling at least in part through the modulation of adhesion and infiltration of LFA-1+ macrophages in the heart.

Integrins: An Important Link between Angiogenesis, Inflammation and Eye Diseases

This review presents the available evidence from human and animal research into integrin structure, classification, function and their role in inflammation, infection and angiogenesis in ocular diseases.

Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine

The immunomodulatory mechanisms of DED and the latest research progress of its related treatments including Chinese medicine will be discussed.



Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.

The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

SAR 1118 appears to be an effective anti-inflammatory treatment for KCS and additional studies are warranted to establish the efficacy of SAR 1118 for the treatment of KCS in humans.

Adaptor regulation of LFA‐1 signaling in T lymphocyte migration: Potential druggable targets for immunotherapies?

The complexity of the LFA‐1‐associated signaling delineated in this review suggests that it may be an important and challenging focus for future research, enabling the identification of “tunable” targets for the development of immunotherapies.

Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.

  • C. SembaD. Swearingen T. Gadek
  • Medicine
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2011
SAR 1118 Ophthalmic Solution appears safe and well-tolerated up to 5.0% TID in healthy adult subjects and tear PK profiles support a QD/BID dosing schedule.

Organization of the integrin LFA-1 in nanoclusters regulates its activity.

It is concluded that besides affinity regulation, LFA-1 function is controlled by at least three different avidity patterns: random distributed inactive molecules, well-defined ligand-independent proactive nanoclusters, and lig and-triggered micrometer-sized macroclusters.

Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes

In assays of adhesion of resting lymphocytes to purified LFA-1, ICAM-3 is by far the most functionally important ICAM, implying an important role for ICam-3 in the generation of immune responses.

The role of the integrin LFA‐1 in T‐lymphocyte migration

It is speculated that T cells have evolved a mode of rapid migration that is of paramount importance in achieving the high‐speed immune surveillance upon which depends the body’s protection against diverse invaders from pathogens to cancer cells.

IL-17 disrupts corneal barrier following desiccating stress

Findings suggest that IL-17 has a role in corneal epithelial barrier disruption in DE and antibody neutralization of IL- 17 ameliorated experimental DE-induced cornea and conjunctiva dysfunction.